Predict your next investment

Venture Capital
reimaginedventures.com

See what CB Insights has to offer

Investments

20

Portfolio Exits

2

About Reimagined Ventures

Reimagined Ventures invests in companies across a range of industries and asset classes. The firm focuses on finding the businesses and entrepreneurs who are upending the status quo and rethinking old ways to create something new.

Reimagined Ventures Headquarter Location

1001 Green Bay Rd #317

Winnetka, Illinois, 60093,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Reimagined Ventures News

Swiss-based Debiopharm co-invests in the future of cell therapies on a chip through the latest $25 million Series A round for Mekonos

Nov 10, 2021

Lausanne, Switzerland - San Francisco (ots) - Funding to accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships Debiopharm ( www.debiopharm.com ), a Swiss biopharmaceutical company, announced today having invested $4M in Mekonos , a biotech company building the future of cell therapies on a chip. This financing is part of a $25M, Series A investment round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. Debiopharm’s is one of the new institutional and strategic investors which also include Section 32, Sands Capital, TDK Ventures, along with previous investors, including Novartis Pharma AG and Elementum Ventures. This funding round will support Mekonos’ next stages in product development and commercialization. Mekonos will use the new capital specifically to expand its MEMS, Microfluidics, Biology, and Business Development functions in order to advance its proprietary, integrated system-on-a-chip (SoC) for targeted ex vivo gene engineering. The platform supports physical delivery of payloads at the single cell level, as well as the parallel delivery of multiple payloads– multiplexing – into cells with repeatable and localized dose control for precise and scalable cell engineering. Demonstration pilot projects with top pharmaceutical and research labs have shown outstanding cell viability and uptake in delivery of CRISPR and CRE into iPSCs and other fragile cell types. The field of cell & gene therapy has seen tremendous progress, reaching impressive clinical milestones over the last few years. Examples include CAR-T therapies to treat blood malignancies along with several gene therapies, including the first clinical readouts with CRISPR-based technologies. The field, however, is limited by several medical and technical limitations, in particular payload delivery, viability of cells, and reliable manufacturing. The California based biotech, Mekonos, is responding to several of these challenges with a versatile cell engineering platform using a microfluidic chip allowing single cell capture and a BioMEMS chip of nanoneedles that can deliver different types of payloads directly into cells. “Mekonos is bringing truly disruptive cell engineering technology to reality. This investment aligns well with our aim to support the development of novel drug delivery systems and further explore the possibilities that digital platforms can bring to science and ultimately patients. We look forward to observing firsthand the improvements that Mekonos’ plateform can bring to cell and gene therapeutics,” expressed Lambert Potin, Partnering Associate, Search and Evaluation, Debiopharm. “It’s thrilling to collaborate on this investment with a syndicate of strong investors for such an important cutting-edge biotechnology. It’s evident that the versatility of Mekonos’ platform will take cell and gene engineering far beyond CAR-T and what we know today,” explained Tanja Dowe, CEO, Debiopharm Innovation Fund. About Mekonos, Inc. Mekonos is a cell & gene technology company transforming synthetic biology and personalized medicine. The company's SoC merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale. The company is headquartered in San Francisco, is backed by leading investors in both healthcare and technology, and is an alum of Berkeley Launch, Berkeley SkyDeck, Creative Destruction Lab, and named a 2018 Fierce 15 startup. For more information please visit www.mekonos.com Debiopharm’s commitment to patients Debiopharm develops, manufactures and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections. We aim to provide strategic funding and guidance for companies with Smart Data & Digital Health solutions with the ambition to change the way drugs are developed and the way patients are treated. Our growing portfolio company achievements includes 18 FDA clearances or CE marks and 2 IPOs. Since 2018 Debiopharm has invested over USD 120 million, typically leading the investment rounds of its 16 portfolio companies. For more information, please visit www.debiopharm.com We are on Twitter. Follow us @DebiopharmNews and @debiopharmfund Rückfragen & Kontakt:

Reimagined Ventures Investments

20 Investments

Reimagined Ventures has made 20 investments. Their latest investment was in Mekonos as part of their Series A on November 11, 2021.

CBI Logo

Reimagined Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/9/2021

Series A

Mekonos

$25M

Yes

10

9/28/2021

Series C

NovaSignal

$37M

No

10

9/16/2021

Series B

Outer

$50M

No

13

9/15/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2021

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/9/2021

9/28/2021

9/16/2021

9/15/2021

9/14/2021

Round

Series A

Series C

Series B

Series D

Series E

Company

Mekonos

NovaSignal

Outer

Subscribe to see more

Subscribe to see more

Amount

$25M

$37M

$50M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

10

13

10

10

Reimagined Ventures Portfolio Exits

2 Portfolio Exits

Reimagined Ventures has 2 portfolio exits. Their latest portfolio exit was SomaLogic on March 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/29/2021

Acq - Pending

$99M

3

2/4/2021

Acquired

Subscribe to see more

Subscribe to see more

10

Date

3/29/2021

2/4/2021

Exit

Acq - Pending

Acquired

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

3

10

Reimagined Ventures Team

3 Team Members

Reimagined Ventures has 3 team members, including current Founder, Managing Director, Alec Litowitz.

Name

Work History

Title

Status

Alec Litowitz

Founder, Managing Director

Current

Josh Porter

Managing Partner

Current

Josh Porter

Goldman Sachs, and Point72 Asset Management

Managing Director

Former

Name

Alec Litowitz

Josh Porter

Josh Porter

Work History

Goldman Sachs, and Point72 Asset Management

Title

Founder, Managing Director

Managing Partner

Managing Director

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.